Provectus Pharmaceuticals' PV-10 Data to Be Presented at ESMO 2012 on October 1, 2012

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Jul 17, 2012 - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that data on PV-10 for metastatic melanoma will be presented at the ESMO 2012 (European Society for Medical Oncology) Congress in Vienna, Austria on October 1, 2012.

Dr. Sanjiv Agarwala, M.D., Principal Investigator for the PV-10 Phase 2 trial, and Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA, will be presenting PV-10 data included in Abstract #1137P, in a poster presentation entitled, "Immuno-chemoablation of metastatic melanoma with intralesional rose bengal," authored by S.S. Agarwala, J.F. Thompson, B.M. Smithers, M. Ross, B.J. Coventry, D.R. Minor, C.R. Scoggins and E. Wachter. The poster will be presented during Poster Presentation III, in Hall XL, from 1:00 p.m. - 2:00 p.m. local time.

Dr. Craig Dees, PhD, CEO of Provectus said, “We are pleased to be accepted by ESMO, one of the most prestigious European organizations, and look forward to reaching a global audience, as we continue in our path towards regulatory approval of PV-10."

About ESMO

The European Society for Medical Oncology (ESMO) is the leading European professional organization, committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care. Since its founding in 1975 as a non-profit organization, ESMO's mission has been to advance cancer care and cure. It achieves this through fostering and disseminating good science that leads to better medicine and determines best practice. In this way ESMO fulfills its goal to support oncology professionals in providing people with cancer the most effective treatments available and the high-quality care they deserve.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

 

Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
CFO, COO
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, VP – Investor Relations
or
Bill Gordon, SVP – Media Relations
212-564-4700

 

Posted: July 2012

View comments

Hide
(web5)